Moors & Cabot’s AbbVie ABBV Stock Holding History

Moors & Cabot’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Hold	0	–	-$1.61K	–	845
2023 Q1	–	Sell	-500	Closed	-$76.4K	–	873
2022 Q4	$6.55K	Hold	500	–	–	﹤0.01%	832
2022 Q3	$2K	Buy	+500	New	+$71.7K	﹤0.01%	813
2020 Q3	–	Sell	-2,100	Closed	-$7K	–	708
2020 Q2	$7K	Buy	+2,100	New	+$185K	﹤0.01%	655
2019 Q4	–	Sell	-35,000	Closed	-$27K	–	621
2019 Q3	$27K	Buy	+35,000	New	+$2.4M	﹤0.01%	637
2016 Q1	–	Sell	-2,500	Closed	-$8K	–	522
2015 Q4	$8K	Hold	2,500	–	–	﹤0.01%	507
2015 Q3	$6K	Buy	+2,500	New	+$163K	﹤0.01%	502

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Moors & Cabot's ABBV Position: Q1 2026 in Review

Moors & Cabot increased its AbbVie (ABBV) stake by 2.1% in Q1 2026, buying an estimated $325K and bringing the position to 70,291 shares worth $15.3M. The position accounts for 0.65% of the portfolio, ranked #30.

Moors & Cabot first reported a position in ABBV in Q1 2014 and has held it in 49 quarters since. The position peaked at $15.8M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Moors & Cabot held 70,291 shares of AbbVie worth $15.3M as of Q1 2026.
Moors & Cabot bought 1,466 AbbVie shares in Q1 2026, an estimated $325K.
AbbVie made up 0.65% of Moors & Cabot's portfolio in Q1 2026, its #30 holding.
Moors & Cabot first reported a position in AbbVie in Q1 2014 and has held it in 49 quarters since.
Moors & Cabot's AbbVie position peaked at $15.8M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.